tetano
Editor, Senior Moderator
J Infect Chemother. 2015 Feb 7. pii: S1341-321X(15)00036-7. doi: 10.1016/j.jiac.2015.01.015. [Epub ahead of print]
[h=1]Influenza vaccination during pregnancy and its usefulness to mothers and their young infants.[/h] Takeda S[SUP]1[/SUP], Hisano M[SUP]2[/SUP], Komano J[SUP]3[/SUP], Yamamoto H[SUP]1[/SUP], Sago H[SUP]2[/SUP], Yamaguchi K[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The current approach to protecting pregnant women from influenza infection and serious influenza-related complications is vaccination. It is, therefore, critical to evaluate the vaccine's safety, immunogenicity, and protection efficacy during pregnancy. However, because it is affected by previous influenza vaccination or infection, the efficacy of the seasonal trivalent inactivated influenza vaccine is difficult to evaluate in pregnant women. The A/H1N1pdm pandemic in 2009 provided us with the opportunity to evaluate the immunogenicity of the influenza vaccine unaffected by previous vaccinations or infections. Vaccination with inactivated influenza virus during pregnancy elicited neutralizing antibody titers that were sufficient and comparable to those of naturally infected individuals. Furthermore, post-pandemic surveys provided a wealth of definitive information on vaccine efficacy and safety. In addition, transplacental transfer of antibodies following vaccination protected newborn infants against influenza infection. With reports showing the effectiveness of influenza vaccine during pregnancy, it is suggested that influenza vaccination benefits both mothers and their young infants.
Copyright ? 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Immunogenicity; Influenza; Pregnancy; Transplacental transfer; Vaccine; Vaccine safety
PMID: 25708925 [PubMed - as supplied by publisher]
[h=1]Influenza vaccination during pregnancy and its usefulness to mothers and their young infants.[/h] Takeda S[SUP]1[/SUP], Hisano M[SUP]2[/SUP], Komano J[SUP]3[/SUP], Yamamoto H[SUP]1[/SUP], Sago H[SUP]2[/SUP], Yamaguchi K[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The current approach to protecting pregnant women from influenza infection and serious influenza-related complications is vaccination. It is, therefore, critical to evaluate the vaccine's safety, immunogenicity, and protection efficacy during pregnancy. However, because it is affected by previous influenza vaccination or infection, the efficacy of the seasonal trivalent inactivated influenza vaccine is difficult to evaluate in pregnant women. The A/H1N1pdm pandemic in 2009 provided us with the opportunity to evaluate the immunogenicity of the influenza vaccine unaffected by previous vaccinations or infections. Vaccination with inactivated influenza virus during pregnancy elicited neutralizing antibody titers that were sufficient and comparable to those of naturally infected individuals. Furthermore, post-pandemic surveys provided a wealth of definitive information on vaccine efficacy and safety. In addition, transplacental transfer of antibodies following vaccination protected newborn infants against influenza infection. With reports showing the effectiveness of influenza vaccine during pregnancy, it is suggested that influenza vaccination benefits both mothers and their young infants.
Copyright ? 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Immunogenicity; Influenza; Pregnancy; Transplacental transfer; Vaccine; Vaccine safety
PMID: 25708925 [PubMed - as supplied by publisher]